High-Dose Chemotherapy Followed by ASCT Improves Survival Compared with Non-myeloablative Consolidation in Primary CNS Lymphoma By Ogkologos - August 20, 2026 3 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MATRix/IELSG43 study Source RELATED ARTICLESMORE FROM AUTHOR Belzutifan Plus Lenvatinib Improves Outcomes Over Cabozantinib in Patients with Advanced RCC Following Progression to PD1 or PD-L1 Inhibitors Combining 177Lu-PSMA-617 with ADT Plus ARPI Prolongs rPFS in Patients with PSMA-positive Metastatic Androgen Pathway Modulator-Naive/Sensitive Prostate Cancer EMA Recommends Extension of Therapeutic Indications for Cetuximab MOST POPULAR Why the voices of people affected by cancer are critical to... November 23, 2020 Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context May 22, 2026 Trametinib Is a New Treatment Option for Rare Form of Ovarian... March 10, 2022 Flame of Hope Awards: Celebrating our volunteers April 3, 2023 Load more HOT NEWS Whole-Genome Sequencing Provides Rapid and Accurate Genomic Profiling in Patients with... Minimizing Time Between Diagnosis and End of Treatment Improves Breast Cancer... Reflections on My First Year as NCI Director Efficacy Outcomes of Olaparib in Patients with mCRPC with BRCA Alterations...
